FY2024 EPS Estimates for Unity Biotechnology, Inc. Boosted by Analyst (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – Equities research analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Unity Biotechnology in a research report issued to clients and investors on Tuesday, April 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($2.42) for the year, up from their prior estimate of ($3.83). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($0.29) EPS.

Unity Biotechnology Stock Performance

UBX stock opened at $1.51 on Thursday. The company’s 50 day moving average price is $1.66 and its 200 day moving average price is $1.78. Unity Biotechnology has a fifty-two week low of $1.50 and a fifty-two week high of $3.82.

Institutional Investors Weigh In On Unity Biotechnology

Several large investors have recently modified their holdings of UBX. Vanguard Group Inc. raised its position in Unity Biotechnology by 246.2% in the third quarter. Vanguard Group Inc. now owns 4,437,259 shares of the company’s stock worth $1,753,000 after acquiring an additional 3,155,586 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Unity Biotechnology by 65.2% in the 3rd quarter. Renaissance Technologies LLC now owns 1,582,369 shares of the company’s stock valued at $625,000 after buying an additional 624,651 shares during the period. Armistice Capital LLC purchased a new stake in Unity Biotechnology in the 4th quarter valued at about $1,328,000. Acadian Asset Management LLC grew its holdings in shares of Unity Biotechnology by 39.8% during the 1st quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock worth $435,000 after purchasing an additional 111,097 shares during the period. Finally, State Street Corp grew its holdings in shares of Unity Biotechnology by 32.4% during the 3rd quarter. State Street Corp now owns 172,640 shares of the company’s stock worth $68,000 after purchasing an additional 42,200 shares during the period. 29.49% of the stock is owned by institutional investors and hedge funds.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.